Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256204
Status:
COMPLETED
Last Update Posted:
2012-01-12
First Post:
2005-11-16
Brief Title:
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinsons Disease
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Multi Center Double Blind Randomized Start Placebo-Controlled Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinsons Disease Subjects
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ADAGIO
Brief Summary:
A 2 phase study to evaluate disease progression in Parkinsons disease patients taking rasagiline
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None